Related Experiment Video

Updated: Dec 20, 2025

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.2K

Evolving Therapeutic Options for Chronic Graft-versus-Host Disease

Rebecca M Gonzalez1,2, Joseph Pidala1

  • 1Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida, USA.

Pharmacotherapy
|May 23, 2020
PubMed

Insights

Chronic graft-versus-host disease (cGVHD) significantly impacts allogeneic transplant patients despite treatment advances. New strategies, including novel agents and expanded cyclophosphamide use, are improving prevention and treatment outcomes for this late complication.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality in allogeneic transplant recipients.
  • It is influenced by donor, patient, and hematopoietic cell transplant (HCT) factors, presenting significant post-transplant complications.
  • Understanding cGVHD pathophysiology is crucial for developing improved clinical interventions.

Purpose of the Study:

  • To review recent advances in understanding cGVHD pathophysiology.
  • To highlight new approaches for the prevention and treatment of cGVHD.
  • To discuss the impact of novel agents and expanded therapeutic strategies.

Main Methods:

  • Review of current literature on cGVHD.
  • Analysis of recent clinical trials and therapeutic advancements.
  • Discussion of emerging biological insights into cGVHD.

Main Results:

  • Posttransplantation cyclophosphamide shows promise beyond haploidentical HCTs, transforming outcomes.
  • Novel agents are being investigated in combination with corticosteroids for upfront therapy.
  • Ibrutinib is the first FDA-approved agent for cGVHD, marking a significant therapeutic advance.
  • Several treatment options for steroid-refractory cGVHD are under investigation.

Conclusions:

  • Advances in understanding cGVHD pathophysiology are driving innovation in prevention and treatment.
  • Expanded use of posttransplantation cyclophosphamide and novel therapeutic agents offer improved outcomes.
  • Future research focuses on mitigating steroid exposure and managing refractory disease.

Keywords:
GVHD novel targetsallogeneic cell transplantationchronic GVHDchronic graft-versus-host diseasesteroid-refractory cGVHD

More Related Videos

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.5K
Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

10.1K

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
794
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
83.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
381
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
374